MHCII 限制表明 B 细胞在体内激活肿瘤特异性 CD4+ T 细胞的能力非常有限

IF 7.2 2区医学 Oncoimmunology Pub Date : 2023-12-10 DOI:10.1080/2162402x.2023.2290799

Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth

{"title":"MHCII 限制表明 B 细胞在体内激活肿瘤特异性 CD4+ T 细胞的能力非常有限","authors":"Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth","doi":"10.1080/2162402x.2023.2290799","DOIUrl":null,"url":null,"abstract":"There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capa...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo\",\"authors\":\"Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth\",\"doi\":\"10.1080/2162402x.2023.2290799\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capa...\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402x.2023.2290799\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2023.2290799","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

人们越来越关注 B 细胞在抗肿瘤免疫中的作用以及在采纳性细胞疗法中的潜在用途。迄今为止，这种疗法的成功率有限。B细胞的固有能力和免疫功能是导致这种疗法失败的主要原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo

There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capa...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.